Press Release – Page 2

PaxMedica, Inc. Enters Into Committed Equity Investment Agreement for up to $20 Million With Lincoln Park Capital

Thu November 17, 2022 | 07:56 pm

PaxMedica, Inc. Enters Into Committed Equity Investment Agreement for up to $20 Million With Lincoln Park Capital

January 4, 2023
By tardimed
0 comments

Agreement Provides Flexible Funding on Path to NDA Submission for PAX-101- TARRYTOWN, NY, Nov. 17, 2022 (GLOBE NEWSWIRE) -- via NewMed...

PaxMedica Initiates Clinical Program to Advance PAX-101 Towards FDA Submission

Tue November 8, 2022 | 07:55 pm

Press Release

PaxMedica Initiates Clinical Program to Advance PAX-101 Towards FDA Submission

January 4, 2023
By tardimed
0 comments

Final Study Results are Expected in First Half of 2023 TARRYTOWN, NY, Nov. 08, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – PaxMedica, ...

PaxMedica Appoints Stefan Schwabe MD, PhD as Chief Medical Officer

Mon October 24, 2022 | 07:52 pm

Press Release

PaxMedica Appoints Stefan Schwabe MD, PhD as Chief Medical Officer

January 4, 2023
By tardimed
0 comments

Dr. Schwabe brings 30+ years of Clinical Experience in the Pharmaceutical Industry TARRYTOWN, NY, Oct. 24, 2022 (GLOBE NEWSWIRE) -- v...

Visiox Pharma Appoints Industry Veteran Cynthia Matossian, M.D., as Chief Medical Officer

Thu October 13, 2022 | 07:50 pm

Press Release

Visiox Pharma Appoints Industry Veteran Cynthia Matossian, M.D., as Chief Medical Officer

January 4, 2023
By tardimed
0 comments

TARRYTOWN, N.Y., Oct. 13, 2022 /PRNewswire/ -- Visiox Pharma, LLC., a privately funded biopharmaceutical company focused on the develop...

PaxMedica Appoints Specialty Pharma Industry Leader Charles J. Casamento to Its Board of Directors

Sat October 8, 2022 | 07:44 pm

Press Release

PaxMedica Appoints Specialty Pharma Industry Leader Charles J. Casamento to Its Board of Directors

January 4, 2023
By tardimed
0 comments

Founder of several public life sciences companies including Questcor, Osteologix and Indevus, Casamento will serve as an Independent Di...

PaxMedica, Inc. Announces Pricing of Initial Public Offering

Fri August 26, 2022 | 08:00 am

Press Release

PaxMedica, Inc. Announces Pricing of Initial Public Offering

September 1, 2022
By tardimed
0 comments

Shares will Trade on Nasdaq Capital Market under Ticker Symbol “PXMD” TARRYTOWN, NY, Aug. 26, 2022 (GLOBE NEWSWIRE) -- via NewMediaW...

Timber Pharmaceuticals Announces Closing of $8.0 Million Public Offering

Mon August 8, 2022 | 04:06 pm

Press Release

Timber Pharmaceuticals Announces Closing of $8.0 Million Public Offering

August 15, 2022
By tardimed
0 comments

Basking Ridge, NJ, Aug. 08, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE...

Visiox Pharma Announces Close of $7M Seed Round

Wed August 3, 2022 | 08:45 am

Press Release

Visiox Pharma Announces Close of $7M Seed Round

August 15, 2022
By tardimed
0 comments

Funding to facilitate NDA filings, inventory manufacturing, and commercial infrastructure buildout TARRYTOWN, N.Y., Aug. 3, 2022 /PR...

Timber Pharmaceuticals Announces First Patients Enrolled in Phase 3 ASCEND Clinical Trial Evaluating TMB-001 in Congenital Ichthyosis

Thu June 23, 2022 | 09:37 am

Press Release

Timber Pharmaceuticals Announces First Patients Enrolled in Phase 3 ASCEND Clinical Trial Evaluating TMB-001 in Congenital Ichthyosis

August 15, 2022
By tardimed
0 comments

Pivotal Trial Expected to Enroll More Than 140 Patients With Moderate to Severe Congenital Ichthyosis at Leading Research Centers in th...

Visiox Pharma Appoints Industry Veteran Vicente Anido Jr., Ph.D., as a Strategic Advisor

Wed June 15, 2022 | 08:36 am

Press Release

Visiox Pharma Appoints Industry Veteran Vicente Anido Jr., Ph.D., as a Strategic Advisor

August 15, 2022
By tardimed
0 comments

Vicente Anido Jr., Ph.D., joins as a Strategic Advisor to advance two products to market and inform growth strategy TARRYTOWN, N.Y.,...

Quick Links

CONTACT INFORMATION